Michael Buitron
@buitron.bsky.social
HIV research and services for over 30 years. #PLWH #UequalsU #HIV testing, PrEP, educator, group facilitator, writer
But unfortunately for Gilead, lenacapavir was so effective, that the outside ethical review panel stopped the clinical trial early.
There wasn't enough statistical power to support expanding Descovy's approval to women and it would be unethical to continue to give women either Descovy or Truvada
There wasn't enough statistical power to support expanding Descovy's approval to women and it would be unethical to continue to give women either Descovy or Truvada
November 14, 2024 at 11:44 PM
But unfortunately for Gilead, lenacapavir was so effective, that the outside ethical review panel stopped the clinical trial early.
There wasn't enough statistical power to support expanding Descovy's approval to women and it would be unethical to continue to give women either Descovy or Truvada
There wasn't enough statistical power to support expanding Descovy's approval to women and it would be unethical to continue to give women either Descovy or Truvada
It made me remember the bar graph in the last post. Why did Gilead do 3 arms, comparing lenacapavir to both Truvada and Descovy, already approved drugs with similar effectiveness?
It's because they could take advantage of the high incidence in Africa to get the restriction on Descovy removed
It's because they could take advantage of the high incidence in Africa to get the restriction on Descovy removed
November 14, 2024 at 11:39 PM
It made me remember the bar graph in the last post. Why did Gilead do 3 arms, comparing lenacapavir to both Truvada and Descovy, already approved drugs with similar effectiveness?
It's because they could take advantage of the high incidence in Africa to get the restriction on Descovy removed
It's because they could take advantage of the high incidence in Africa to get the restriction on Descovy removed
As long as we take our ARVs, resistance shouldn’t emerge spontaneously.
In the pipeline we have more new ways to stop HIV replication, so the future looks good
❤️
In the pipeline we have more new ways to stop HIV replication, so the future looks good
❤️
November 7, 2024 at 5:32 PM
As long as we take our ARVs, resistance shouldn’t emerge spontaneously.
In the pipeline we have more new ways to stop HIV replication, so the future looks good
❤️
In the pipeline we have more new ways to stop HIV replication, so the future looks good
❤️
Today, an INSTI-based regimen (like TLD) can be given immediately, before the patient’s first labs are ordered.
The main way we see resistance is when it happens immediately, like when someone is infected with a resistant strain of HIV. The first VL won’t show a decline.
The main way we see resistance is when it happens immediately, like when someone is infected with a resistant strain of HIV. The first VL won’t show a decline.
November 7, 2024 at 5:31 PM
Today, an INSTI-based regimen (like TLD) can be given immediately, before the patient’s first labs are ordered.
The main way we see resistance is when it happens immediately, like when someone is infected with a resistant strain of HIV. The first VL won’t show a decline.
The main way we see resistance is when it happens immediately, like when someone is infected with a resistant strain of HIV. The first VL won’t show a decline.
INSTIs are in a new class (stopping integration) there was no preexisting resistance.
In wealthy countries, it is a standard practice to order a test that looks at resistance before prescribing.
That way, the doctor’s know what is still effective before prescribing a particular medication.
In wealthy countries, it is a standard practice to order a test that looks at resistance before prescribing.
That way, the doctor’s know what is still effective before prescribing a particular medication.
November 7, 2024 at 5:28 PM
INSTIs are in a new class (stopping integration) there was no preexisting resistance.
In wealthy countries, it is a standard practice to order a test that looks at resistance before prescribing.
That way, the doctor’s know what is still effective before prescribing a particular medication.
In wealthy countries, it is a standard practice to order a test that looks at resistance before prescribing.
That way, the doctor’s know what is still effective before prescribing a particular medication.